Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients

An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice

(2011) E S Gabitzsch et al.   CANCER GENE THERAPY

Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine

(2011) Frank R. Jones et al.   VACCINE

Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine

(2011) Elizabeth S. Gabitzsch et al.   VACCINE

Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA

(2010) Elizabeth S. Gabitzsch et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses

(2010) Claudia Palena et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer

(2010) Michael A. Morse et al.   JOURNAL OF CLINICAL INVESTIGATION

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Dendritic cells and immunity against cancer

(2010) K. Palucka et al.   JOURNAL OF INTERNAL MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

(2009) Celestia S. Higano et al.   CANCER

Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity

(2009) T Osada et al.   CANCER GENE THERAPY

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

(2009) James L. Gulley et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors

(2009) Sergey S Seregin et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity

(2009) Elizabeth S. Gabitzsch et al.   VACCINE

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines

(2008) M. A. Morse et al.   BLOOD

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses

(2008) Elizabeth S. Gabitzsch et al.   IMMUNOLOGY LETTERS

Adenovirus DNA polymerase is recognized by human CD8+ T cells

(2008) A. Joshi et al.   JOURNAL OF GENERAL VIROLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE